Arun Menawat Dr. Acquires 20,000 Shares of Profound Medical Corp. (TSE:PRN) Stock

Profound Medical Corp. (TSE:PRN) Director Arun Menawat Dr. acquired 20,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were purchased at an average cost of C$10.65 per share, with a total value of C$213,000.00.

Profound Medical Stock Performance

TSE:PRN traded up C$0.18 on Tuesday, hitting C$11.04. The company’s stock had a trading volume of 1,100 shares, compared to its average volume of 7,415. The company has a current ratio of 8.61, a quick ratio of 14.98 and a debt-to-equity ratio of 16.95. The stock has a fifty day moving average of C$10.82 and a two-hundred day moving average of C$11.60. Profound Medical Corp. has a one year low of C$9.55 and a one year high of C$15.75. The firm has a market capitalization of C$270.26 million, a P/E ratio of -6.54 and a beta of 0.81.

Analyst Ratings Changes

Separately, Raymond James upgraded Profound Medical to a “strong-buy” rating in a report on Saturday, November 9th.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.